ALGN Stock Analysis: Align Technology | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 12.880m USD | 12M Return: 15.6% | US0162551016 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 156M
EPS Trend: 94.2%
Qual. Beats: 0
Rev. Trend: 93.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Align Technology, Inc. (NASDAQ: ALGN) is a global medical device company specializing in digital dentistry, primarily through its Invisalign clear aligner system, Vivera retainers, and iTero intraoral scanners. The company operates two reportable segments: a Clear Aligner segment that offers a comprehensive range of Invisalign products tailored to different age groups (from children as young as six to adults) and varying treatment complexities, and an Imaging Systems and CAD/CAM Services segment that provides the iTero scanning platform along with associated software tools, restorative and orthodontic design software, and subscription or pay-per-scan services.
The company follows a business-to-business-to-consumer (B2B2C) model, marketing its products to licensed dental and orthodontic practitioners who then prescribe and administer treatment to patients. It generates revenue through product sales, scanner hardware leases or sales, and recurring software and consumable streams. Founded in 1997, headquartered in Tempe, Arizona, and publicly traded since its 2001 IPO, Align competes within the broader Health Care Supplies sub-industry and has historically been a leading disruptor of the traditional metal braces market through its proprietary clear-aligner technology.
- Invisalign teen and adult case shipments drive clear aligner volume
- iTero scanner adoption expands imaging systems and CAD/CAM services revenue
- China and Asia Pacific demand supports international orthodontic growth
| Net Income: 413.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 0.87 > 1.0 |
| NWC/Revenue: 18.23% < 20% (prev 11.41%; Δ 6.81% < -1%) |
| CFO/TA 0.12 > 3% & CFO 755.7m > Net Income 413.6m |
| Net Debt (-981.7m) to EBITDA (786.3m): -1.25 < 3 |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.6m) vs 12m ago -1.33% < -2% |
| Gross Margin: 66.48% > 18% (prev 69.79%; Δ -3.31% > 0.5%) |
| Asset Turnover: 65.52% > 50% (prev 63.75%; Δ 1.76% > 0%) |
| Interest Coverage Ratio: 10.53 > 6 (EBIT TTM 628.6m / Interest Expense TTM 59.7m) |
| A: 0.12 (Total Current Assets 2.66b - Total Current Liabilities 1.91b) / Total Assets 6.42b |
| B: 0.40 (Retained Earnings 2.60b / Total Assets 6.42b) |
| C: 0.10 (EBIT TTM 628.6m / Avg Total Assets 6.32b) |
| D: 1.94 (Book Value of Equity 4.23b / Total Liabilities 2.19b) |
| Altman-Z'' = 4.79 = AA |
| DSRI: 0.95 (Receivables 1.15b/1.15b, Revenue 4.14b/3.96b) |
| GMI: 1.05 (GM 69.79% / 66.48%) |
| AQI: 1.07 (AQ_t 0.41 / AQ_t-1 0.38) |
| SGI: 1.04 (Revenue 4.14b / 3.96b) |
| TATA: -0.05 (NI 413.6m - CFO 755.7m) / TA 6.42b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of August 22, 2026, the stock is trading at USD 162.55 with a total of 1,000,520 shares traded. Over the past week, the price has changed by -10.35%, over one month by -8.42%, over three months by -0.30% and over the past year by +15.55%.
Current recommended Stop Loss: 153.50 (which is 5.6% or 1.3 ATR below the current price).
Align Technology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALGN.
- StrongBuy: 8
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 208.6 | 28.3% |
P/E Trailing = 31.4229
P/E Forward = 16.0514
P/S = 3.1115
P/B = 3.0432
P/EG = 0.858
Revenue TTM = 4.14b USD
EBIT TTM = 628.6m USD
EBITDA TTM = 786.3m USD
Long Term Debt = 86.6m USD (estimated: total debt 120.8m - short term 34.2m)
Short Term Debt = 34.2m USD (from shortTermDebt, last quarter)
Debt = 120.8m USD (from shortLongTermDebtTotal, last quarter) (leases 120.8m already included)
Net Debt = -981.7m USD (calculated: Debt 120.8m - CCE 1.10b)
Enterprise Value = 11.9b USD (12.9b + Debt 120.8m - CCE 1.10b)
Interest Coverage Ratio = 10.53 (Ebit TTM 628.6m / Interest Expense TTM 59.7m)
EV/FCF = 15.75x (Enterprise Value 11.9b / FCF TTM 755.7m)
FCF Yield = 6.35% (FCF TTM 755.7m / Enterprise Value 11.9b)
FCF Margin = 18.26% (FCF TTM 755.7m / Revenue TTM 4.14b)
Net Margin = 9.99% (Net Income TTM 413.6m / Revenue TTM 4.14b)
Gross Margin = 66.48% ((Revenue TTM 4.14b - Cost of Revenue TTM 1.39b) / Revenue TTM)
Gross Margin QoQ = 65.14% (prev 70.82%)
Tobins Q-Ratio = 1.85 (Enterprise Value 11.9b / Total Assets 6.42b)
Interest Expense / Debt = 49.41% (Interest Expense 59.7m / Debt 120.8m)
Taxrate = 27.30% (155.3m / 568.9m)
NOPAT = 457.0m (EBIT 628.6m * (1 - 27.30%))
Current Ratio = 1.40 (Total Current Assets 2.66b / Total Current Liabilities 1.91b)
Debt / Equity = 0.03 (Debt 120.8m / totalStockholderEquity, last quarter 4.23b)
Debt / EBITDA = -1.25 (Net Debt -981.7m / EBITDA 786.3m)
Debt / FCF = -1.30 (Net Debt -981.7m / FCF TTM 755.7m)
Total Stockholder Equity = 4.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.55% (Net Income 413.6m / Total Assets 6.42b)
RoE = 10.09% (Net Income TTM 413.6m / Total Stockholder Equity 4.10b)
RoCE = 15.03% (EBIT 628.6m / Capital Employed (Equity 4.10b + L.T.Debt 86.6m))
RoIC = 10.54% (NOPAT 457.0m / Invested Capital 4.34b)
WACC = 9.80% (E(12.9b)/V(13.0b) * Re(9.55%) + D(120.8m)/V(13.0b) * Rd(49.41%) * (1-Tc(0.27)))
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.73 | Cagr: -2.21%
[DCF] Terminal Value 72.11% ; FCFF base≈724.7m ; Y1≈796.3m ; Y5≈1.01b
[DCF] Fair Price = 187.4 (EV 12.3b - Net Debt -981.7m = Equity 13.3b / Shares 71.0m; r=9.80% [WACC]; 5y FCF grow 11.41% → 2.50% )
EPS Correlation: 94.17 | EPS CAGR: 10.01% | SUE: -0.21 | # QB: 0
Revenue Correlation: 93.70 | Revenue CAGR: 2.42% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.79 | Chg30d=-3.69% | Revisions=-69% | Analysts=14
EPS current Year (2026-12-31): EPS=11.29 | Chg30d=-0.62% | Revisions=-44% | GrowthEPS=+7.4% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=12.55 | Chg30d=+1.46% | Revisions=+39% | GrowthEPS=+11.1% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -25% (up=15, down=26)